IMF Videos Search Content For Healthcare Professional (96) Healthcare Provider (96) Series - Any - About the IMF (2) ASCO/EHA (71) ASH (102) Ask Dr. Durie (149) Black Swan Research Initiative (7) Community Workshops (5) Emerging Therapies (18) Facebook Live (21) Health Equity (14) IMF History (3) IMWG (12) Inspirational (15) Living Well with Myeloma (33) Myeloma in a Minute (25) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (11) Q&A (22) Recent News and Developments (5) Treatments (3) Trending Searches in Myeloma (4) Topics Clinical Trials (60) Financial Considerations (1) Frontline Therapy (10) Health Equity (8) Inspirational Stories (1) Lab & Imaging Tests (14) Recorded Webinars (1) Relapse/Refractory Myeloma (30) Research Updates (69) Symptom Management (4) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (15) High-Risk Myeloma (12) High-risk Smoldering Myeloma (7) Late Relapse (4–6 Lines of Therapy) (25) MGUS (16) Newly Diagnosed (Pre-Treatment or First Treatment) (19) Smoldering Myeloma (15) Types of Therapy Immunomodulatory drugs (IMiDs) (18) Immunotherapies (CAR T; BiTE, etc.) (27) Monoclonal antibodies (12) Proteasome inhibitors (14) Stem cell transplant (13) Steroids (10) Supportive Care (8) Year Published 2026 (7) 2025 (23) 2024 (22) 2023 (19) 2022 (13) 2021 (7) 2020 (1) 2019 (8) 2018 (1) 2016 (1) Trusted Voices Dr. María-Victoria Mateos (6) Dr. Shaji Kumar (2) Dr. Joseph Mikhael (1) Dr. Saad Usmani (1) Dr. Sigurður Kristinsson (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from iStopMM December 22, 2021 ASH Estimating Selection Bias in Previous MGUS Research – the Importance of Screening: Results from the Population-Based Screening Study iStopMM December 20, 2021 ASH Global Treatment Patterns and Outcomes Among Patients with Chromosome Translocation (11;14)-Positive Multiple Myeloma December 15, 2021 ASH Defining New Reference Intervals for Serum Free Light Chains in Individuals with Reduced Kidney Function: Results of the Population- Based on iStopMM Study December 15, 2021 ASH Prevalence of Smoldering Multiple Myeloma: Results from the iStopMM Study December 15, 2021 ASH High Prevalence of Monoclonal Gammopathy in a Population at Risk: The First Results of the PROMISE Study December 13, 2021 ASH Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial December 13, 2021 ASH A Phase 1 Study of AMG 701 in Subjects With Relapsed/Refractory Multiple Myeloma December 8, 2020 ASH La espectrometría de masa Qip en pts con MM de alto riesgo latente incluidos en el ensayo GEM-CESAR December 13, 2019 ASH 4-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone December 13, 2019 ASH Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy December 11, 2019 ASH Estrategia curativa (GEM-CESAR) para el mieloma latente de alto riesgo (SMM) December 11, 2019 ASH Load More
